A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
about
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.In vitro ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Physiological, pharmacokinetic and liver metabolism comparisons between 3-, 6-, 12- and 18-month-old male Sprague Dawley rats under ketamine-xylazine anesthesiaMicrodosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer.Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid.CYP3A activity: towards dose adaptation to the individual.Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics.Personalized Drug Dosage - Closing the Loop.Use of microdose phenotyping to individualise dosing of patients.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.An ultra-sensitive LC-MS/MS method to determine midazolam levels in human plasma: development, validation and application to a clinical study.Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.Pharmacokinetic interaction of intravenous fentanyl with ketoconazole.Effect of brivaracetam on CYP3A activity, measured by oral midazolam.Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.Can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam.Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation.Normal CYP3A activity during arsenic trioxide therapy
P2860
Q35023726-E2DFCC7A-EB01-4C8A-B534-43AE6017A43BQ35147119-8BEC30A3-41C4-4B56-9C81-F1A8332BAE45Q36072448-531CD5C3-6906-42AF-A53C-69350ACEA0BDQ36666343-BBBFEBC4-A42A-474E-B16E-9276B494F986Q37701128-2260ABEC-0FAD-43B9-A4C2-653BFF04F2F6Q37742001-73A6DB79-32AF-4EE2-8DED-C46AA155ADA0Q38397138-13F3472A-591C-43CB-81D2-37E4F70D82CFQ38763583-52202B4F-FECC-49FA-8A7E-57E56CCFFA5EQ39798811-89019925-380E-46C1-9558-2E6B25499A3BQ40186032-8E3EA7DE-DD2A-419E-A120-FF567435C6B2Q40956598-A664152D-6901-42DC-95E9-705CAA2C7D7DQ40996401-CFECD56F-A673-40C4-B30E-91A14A3D90B6Q41328717-070B7711-815F-4EDC-9DF2-BB401BD6C945Q43127353-E2B149E8-F59A-4E4D-8063-C964FD807519Q45279289-1A0DC183-A31A-4091-9F69-63BE991143CEQ47339027-7A52A9ED-82F0-42BC-97E8-43D2F76604E6Q47400081-17101F90-EEE5-4ED5-9F80-561844FCCF73Q47425844-42A979B3-2D85-48F7-BF99-2720A1510618Q47752672-F1CD20E7-E4B8-483E-A31E-490AF33527ECQ47774665-106AFD6E-B975-4D74-8451-01430781BF4BQ47793459-A8E52136-95E0-4525-AE2D-2B74F8275986Q47913545-3C68D1FC-51D4-48DC-873B-D0B1B64057A2Q47915243-D9AA1724-E66D-4624-B2E8-B6576DBAE7C7Q47924035-4F75A5FA-AD1C-4B12-9887-DC09A4F4D0F5Q48333024-C3B1D6CB-63CC-4BC2-8113-D18F5663D62CQ54420274-CB92B52A-563E-4F3B-898B-D6CA6E8E493EQ56832232-7F908533-80E8-4745-AF5B-BC6EF68FE02B
P2860
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
@en
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
@nl
type
label
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
@en
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
@nl
prefLabel
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
@en
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
@nl
P2860
P50
P356
P1476
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions
@en
P2093
P2860
P304
P356
10.1038/CLPT.2013.27
P407
P577
2013-02-08T00:00:00Z